EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19)

Antonios M Diab iD, Hailey M Stack, Brendan T McKeown iD, Bruce C Carleton, Kerry B Goralski iD

Canadian Journal of Physiology and Pharmacology · 2025

DOI: 10.1139/cjpp-2024-0055 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von Antonios M Diab und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, Canada. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Clinical Trials as Topic, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitacs, Canadian Society of Pharmacology and Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In response to the COVID-19 pandemic, Canadian clinical researchers pivoted their research programs to investigate repurposing drugs, accelerating the development of experimental therapies, and developing novel disease-specific treatments. This systematic review analyzes the trial design, participant characteristics, and reported outcomes of all Health Canada authorized clinical trials of therapeutics to prevent or treat COVID-19 with published results as of March 2023. We conclude that there is a need for adaptive clinical trial designs, broader pan-Canadian clinical trial networks, more targeted participant recruitment to facilitate increased diversity and inclusion, and standardization in reporting participant characteristics, outcome measurement, and follow-up. Finally, guided by our findings, we make recommendations for improved clinical trial designs when faced with an emerging disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 Drug TreatmentClinical Trials as TopicAntiviral AgentsHumansCanadaSARS-CoV-2Research DesignDrug Repositioning

Stichwörter der Autor:innen

COVID therapeuticsCOVID-19Health Canadaclinical trialsvaccines

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, Canada.
  • Primary Health Care, Nova Scotia Health Authority, Halifax, NS, Canada.
  • Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
  • Department of Biology, Faculty of Science, Dalhousie University, Halifax, NS, Canada.
  • Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
  • BC Children's Hospital Research Institute, Vancouver, BC, Canada.

ORCID-Profile: Antonios M Diab, Brendan T McKeown, Kerry B Goralski

Förderung

  • Mitacs
  • Canadian Society of Pharmacology and Therapeutics

Zitieren

APA

Diab, A., Stack, H., McKeown, B., Carleton, B., & Goralski, K. B. (2025). Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19). Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0055

Vancouver

Diab A, Stack H, McKeown B, Carleton B, Goralski KB. Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19). Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2024-0055

BibTeX
@article{Diab2025,
  author = {Diab, Antonios M and Stack, Hailey M and McKeown, Brendan T and Carleton, Bruce C and Goralski, Kerry B},
  title = {Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19)},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2025},
  doi = {10.1139/cjpp-2024-0055}
}
Kostenlos starten →